REG - Genflow Biosciences - Total Voting Rights

Genflow BiosciencesAnnouncement

31/10/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251031:nRSe3925Fa&default-theme=true

RNS Number : 3925F  Genflow Biosciences PLC  31 October 2025

 

31 October 2025

Genflow Biosciences Plc

Total Voting Rights

Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or "the Company"),
an emerging leader in the field of longevity research, focused on developing
therapeutic solutions for the prevention of age-related diseases, announces
that the total issued share capital of the Company as at 31 October 2025
consists of 493,547,942 Ordinary Shares none of which are held in treasury.
Therefore, the total number of voting rights in the Company is 493,547,942.

The figure of 493,547,942 Ordinary Shares may be used by shareholders of the
Company as the denominator for the calculations by which they will determine
if they are required to notify their investment in, or a change in their
interest in, the share capital of the Company under the Financial Conduct
Authority's Disclosure Guidance and Transparency Rules.

Contacts

 Genflow Biosciences  Harbor Access
 Dr Eric Leire, CEO   Jonathan Paterson, Investor Relations
 +32-477-495-881      +1 475 477 9401
                      Jonathan.Paterson@Harbor-access.com

 

About Genflow Biosciences

Founded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a
biotechnology company headquartered in the UK with R&D facilities in
Belgium, is pioneering gene therapies to decelerate the aging process, with
the goal of promoting longer and healthier lives while mitigating the
financial, emotional, and social impacts of a fast-growing aging global
population. Genflow's lead compound, GF-1002, works through the delivery of a
centenarian variant of the SIRT6 gene which has yielded promising results.
Genflow's 12-month proof-of-concept clinical trial evaluating their
SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other
programs planned include a clinical trial that will explore the potential
benefits of GF-1002 in treating MASH (Metabolic Dysfunction-Associated
Steatohepatitis), the most prevalent chronic liver disease for which there are
no effective treatments. Please visit www.genflowbio.com
(http://www.genflowbio.com/)   and follow the Company on LinkedIn
(https://www.linkedin.com/company/genflow-biosciences/?viewAsMember=true)
 and X (https://x.com/genflowbio) .

 

 

-Ends-

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVRPPGUPUUPAGMB



            Copyright 2019 Regulatory News Service, all rights reserved